Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone Quadrivalent in Healthy Children (2013-2014)
NCT01946425Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2013
- Primary completion
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Number of Participants Reporting Solicited Injection-Site or Systemic Reactions. Started Sep 2013; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01946425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946425.